New cancer clinical trial: Copanlisib and Fulvestrant in Treating Postmenopausal Patients With ER+ and HER2- Metastatic Breast Cancer Progressing After Aromatase and CDK 4/6 Inhibitors Treatment

Published on: January 15, 2019 at 12:00PM
Conditions:   Anatomic Stage IV Breast Cancer AJCC v8;   Estrogen Receptor Positive;   HER2/Neu Negative;   Metastatic Breast Carcinoma;   Metastatic Malignant Neoplasm in the Brain;   Postmenopausal;   Prognostic Stage IV Breast Cancer AJCC v8
Interventions:   Drug: Copanlisib;   Drug: Fulvestrant
Sponsor:   National Cancer Institute (NCI)
Not yet recruiting
http://bit.ly/2Co8CJX